- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01876173
Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator
Development of and Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator
Sudden cardiac death (SCD) due to a ventricular arrhythmia is a serious cause of cardiovascular death in Canada. The implantable cardioverter defibrillator (ICD) offers high-risk patients a treatment option to reduce the incidence of SCD by delivering an internal shock to restore a normal rhythm, if needed. Definitive evidence has established the effectiveness of the ICD for reducing mortality when used as prophylaxis for SCD (a primary prevention indication). Approximately 3,700 new candidates accrue annually. Practice guidelines define the criteria to determine patient ICD candidacy for primary prevention. However, in addition to SCD risk, ICD candidates may have chronic diseases such as diabetes, renal insufficiency, hypertension, and atrial fibrillation. Thus, balancing the benefits and risks of an ICD can become complex, particularly when competing mortality risks are present. Research has recognized human costs associated with device complications and shocks affecting psychological, health related quality of life (HRQL), and morbidity outcomes. The complexities surrounding the long-term benefits/risks, complications, replacements, and shocks, warrant decision support to prepare patients to make decisions. In Canada, there is no clear framework to support patients' decision-making in the context of ICD treatment options. Decision support, using a decision aid, could moderate treatment related uncertainty and prepare patients to make active, informed, quality decisions.
Objectives: 1) develop a decision aid for ICD candidates to support quality decision-making (informed, deliberate, values-based choices), 2) to evaluate the decision aid, and 3) to determine the feasibility of conducting a trial.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8P 2X2
- Hamilton Health Sciences
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Referred for consideration of an ICD(non-CRT)for a primary prevention indication
- English speaking
- able to provide informed consent
Exclusion Criteria:
- unable to understand the decision aid due to a language barrier or visual impairment
- referred for secondary prevention indication
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Patient Decision Aid for an ICD (primary prevention, non-CRT)
The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician.
Values are assessed to reveal which features of each option are important to patients.
|
The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician.
Values are assessed to reveal which features of each option are important to patients.
다른 이름들:
|
|
간섭 없음: Usual care
The control group will not receive the patient decision aid prior to consultation with the physician.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Primary Outcomes(composite): i) decision aid development, and ii) decision aid evaluation.
기간: Phase 1-2 (1- year)
|
Development of the decision aid will be guided by the Ottawa Decision Support Framework (ODSF).
Evaluation will include the Decision Aid Acceptability questionnaire comprised of 10 items including comprehensibility, balance of presentation of information, and overall suitability.
|
Phase 1-2 (1- year)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pilot RCT (feasibility)
기간: Pre-Post consultation - participants will be followed until consultation is completed and at 3 months post consultation (average of 16 weeks)
|
In this feasibility RCT, the feasibility regarding processes (referral and recruitment rates, consent), key to the success of a larger study will be assessed.
This includes successful delivery of the decision aid in an efficient manner, the monitoring of resources (budget), and study management (trial coordination, human resources).
We will assess the proportion of patients who complete the decision aid, quality questionnaires, and missing data.
|
Pre-Post consultation - participants will be followed until consultation is completed and at 3 months post consultation (average of 16 weeks)
|
|
Decision quality measures
기간: Pre consultation (baseline visit)
|
Decision quality, the extent to which patients' decisions are informed (knowledge) and values based (values, preferences, decisional conflict).
|
Pre consultation (baseline visit)
|
|
Decisional Conflict Scale (DCS)
기간: Pre and post consultation- (intervention and usual care group, baseline visit + 1 week post consult)
|
The Decisional Conflict Scale measures a person's perception of the difficulty in making a decision, the extent to which they feel uncertain about treatment options, are knowledgeable about the risks and benefits of options, clear about personal values, and supported in decision making.
The scale has good test-retest reliability (Cronbach's alpha coefficients > 0.78) and predictive validity.
|
Pre and post consultation- (intervention and usual care group, baseline visit + 1 week post consult)
|
|
Sure Test
기간: Pre-consultation - baseline visit
|
The Sure Test is a 4 item decisional conflict screening tool designed for use in clinical practice.
The Sure Test is embedded in the decision aid (intervention group).
|
Pre-consultation - baseline visit
|
|
The Center for Epidemiologic Studies Depression Scale (CES-D)
기간: Pre consultation - baseline visit (intervention and usual care)
|
The CES-D has 20 items that measure depressive symptoms.
The CES-D has good reliability and validity across community and clinical settings.
Associations between depressive symptoms and decision choice will be assessed.
|
Pre consultation - baseline visit (intervention and usual care)
|
|
Preparation for Decision Making scale
기간: Post consultation - up to two weeks post baseline visit (intervention group)
|
The Preparation for Decision Making Scale has 10 categorical items assessing the usefulness of the decision aid in preparing patients to communicate with a health professional.
|
Post consultation - up to two weeks post baseline visit (intervention group)
|
|
The Medical Outcomes Trust Short Form (SF-36v2)
기간: Pre consultation - baseline visit (intervention and usual care)
|
The SF-36 is a reliable and valid generic health related quality of life scale (HRQL) comprised of 36 items.
Associations between HRQL and decision choice will be undertaken.
|
Pre consultation - baseline visit (intervention and usual care)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Vital status
기간: 3 months post baseline visit
|
Alive, deceased
|
3 months post baseline visit
|
|
Implant status
기간: Phase 3, three months post baseline visit
|
Device status - implantable defibrillator/no implantable defibrillator, deferred
|
Phase 3, three months post baseline visit
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sandra L Carroll, PhD, McMaster University
간행물 및 유용한 링크
일반 간행물
- Carroll SL, Stacey D, McGillion M, Healey JS, Foster G, Hutchings S, Arthur HM, Browne G, Thabane L. Evaluating the feasibility of conducting a trial using a patient decision aid in implantable cardioverter defibrillator candidates: a randomized controlled feasibility trial. Pilot Feasibility Stud. 2017 Nov 21;3:49. doi: 10.1186/s40814-017-0189-9. eCollection 2017.
- Carroll SL, McGillion M, Stacey D, Healey JS, Browne G, Arthur HM, Thabane L. Development and feasibility testing of decision support for patients who are candidates for a prophylactic implantable defibrillator: a study protocol for a pilot randomized controlled trial. Trials. 2013 Oct 22;14:346. doi: 10.1186/1745-6215-14-346.
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심혈관 질환에 대한 임상 시험
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.아직 모집하지 않음Crohn & amp;#39; s | Crohn & amp;#39; s Disease (CD)
-
Vanderbilt University Medical CenterTakeda Pharmaceuticals U.S.A., Inc.모집하지 않고 적극적으로염증성 장질환(IBD) | 궤양성 대장염(UC) | Crohn & amp;#39; s Disease (CD)미국
-
Kaohsiung Medical University아직 모집하지 않음폐 선암종 | 폐암(진단) | Condition/Disease
-
Nandakumar NarayananNational Institute of Neurological Disorders and Stroke (NINDS)초대로 등록
-
UNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of Health모집하지 않고 적극적으로
-
Novartis Pharmaceuticals모병류마티스 관절염 (RA) 및 Sjögren 's Disease (SJD)스페인, 프랑스, 독일, 싱가포르
-
University of PennsylvaniaEUSA Pharma, Inc.; Castleman Disease Collaborative Network모병캐슬맨병 | 캐슬맨병 | 거대 림프절 과형성 | 혈관여포 림프 증식증 | 혈관여포 림프절 과형성 | 혈관여포성 림프종 과형성 | GLNH | 과형성, 거대 림프절 | 림프절 과형성, 거인미국
-
Jiulongpo No.1 People's HospitalJiangxi Maternal and Child Health Hospital아직 모집하지 않음